JP2017521448A - 即時放出性乱用抑止性液体充填剤形 - Google Patents
即時放出性乱用抑止性液体充填剤形 Download PDFInfo
- Publication number
- JP2017521448A JP2017521448A JP2017502652A JP2017502652A JP2017521448A JP 2017521448 A JP2017521448 A JP 2017521448A JP 2017502652 A JP2017502652 A JP 2017502652A JP 2017502652 A JP2017502652 A JP 2017502652A JP 2017521448 A JP2017521448 A JP 2017521448A
- Authority
- JP
- Japan
- Prior art keywords
- capsule
- peg
- daltons
- abuse
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本出願は、2014年7月17日出願の米国仮出願第62/025,878号に基づく優先権を主張するものであり、その開示内容が全体にわたって参照により本明細書に組み込まれる。
[実施例1]
即時放出性ADF液体充填カプセル剤についての最初の試験及び評価実験は、APIをPEG中に懸濁し、これを重量により硬ゼラチンカプセルに充填し、次いでこれが室温で蝋状物質に凝固することに基づいていた。これらの実験の一部では、C-II麻薬の代わりにトレーサー薬物としてアセトアミノフェン(APAP)を使用した。オキシコドンHCl及びAPAPはともに、脱気水に可溶である。プールされた酒石酸水素ヒドロコドン及びアセトアミノフェン錠剤についてのUSPモノグラフは、0.1N HCl中で30分で両薬物が80%(Q)+10%を放出することを規定しており、両方が即時放出可能であることを示している。結果として、APAPが実験における使用可能な代替物であることが予期された。
PEG35000を含む即時放出性ADF液体充填カプセル剤
各種の量のPEG1450及びPEG35000を含むさらなる即時放出性ADFオキシコドンHCl液体充填カプセル製剤の溶出率、ADF特性及び溶融温度を評価した。アセトアミノフェン(APAP)をオキシコドンHClについてのトレーサー薬物として使用した。下記の表3に処方を示す。APAPの目標量はカプセルあたり30mg、目標充填重量は100mg(バッチ番号92)又は200mg(バッチ番号93〜94)であった。カプセルはAPAPを30%w/w(バッチ番号92)又は15%w/w(バッチ番号93〜94)含んでいた。サイズ3不透明硬ゼラチンカプセルを使用した。
染料の評価
多数の染料を、静脈内乱用を抑止する可能性について評価した。各種濃度のFD&C青色2号、緑色(FD&C青色2号及びFD&C黄色5号)、FD&C黄色5号、FD&C赤色40号及び灰色染料(FD&C青色1号、FD&C黄色6号、FD&C赤色40号)を、95%エタノール5%精製水(190プルーフ)溶液にこれらを溶解させ、溶液をシリンジフィルターに通すことにより評価した。シリンジ濾過後、染料溶液を色強度について視覚的に評価し、0が無色を示し5が濃く顕著な色を示す0〜5のスケールで等級付けした。下記の表7に示す通り、青色及び緑色染料は低濃度、例えば0.25%w/wで最も高い色強度を示した。濾過前後の灰色染料溶液をそれぞれ図2A及び2Bに示す。灰色染料は特に顕著且つより魅力的でなかった。染料抽出後の許容されるカラースケール判定は、5を最高レベルの色とする1〜5のスケールで4以上である。
即時放出性ADFオキシコドンHCl液体充填カプセル
オピオイド製品の乱用者はしばしば、活性成分のより急速な放出を促進するために、製品に混ぜ物をする。製品は咀嚼及び嚥下、破砕及び吸入、又は、水若しくはアルコールで(破砕するかそのままかのいずれかで)抽出して、静脈内投与に使用可能であるか精製された製品の吹送のために乾燥可能である溶液を生成することができる。製品に混ぜ物をすることにより、製品そのままの摂取により実現されうるよりも急速な活性物質の送達が可能になる。この急速な開始、高度の曝露には、陶酔感、薬物嗜好、及びより高い乱用可能性が伴う。
即時放出性液体充填カプセルPEG製剤の乱用抑止特性
一実施形態において、即時放出性薬物製品を「乱用抑止性」と判断する少なくとも3つの決定要因、すなわち、すりつぶしに対する抵抗性、抽出時の純度、及び抽出後の視覚的評価がある。消化管への溶出率を増大させるために、摂取前に製品の表面積を増大させるように、剤形の切断を行うことができる。すりつぶし又は抽出の効率を増大させるために切断を使用することもできる。しかし、切断単独では、製剤を乱用可能にするには十分でない。鼻腔の血管に即時放出させるために吹送する(鼻から吸引する)目的で、切断よりも効率的に製品の粒径を低下させるために、剤形のすりつぶしを行うことができる。すりつぶしに使用される、容易に入手可能な道具は市販のコーヒーグラインダーである。一実施形態において、薬物製品は、パン内の%物質(500μm以下)が50%以下であれば乱用抑止性であるとみなされる。すりつぶされると経鼻吹送に利用可能な物質(500μm以下)を1剤形ベースで50%以下生ずる剤形は、乱用抑止性であるとみなされる。本研究の目的は、オキシコドンHClの様々な剤形のすりつぶし可能性を決定することであった。テクスチャー解析は、医薬製品の物理的特性を測定するための、医薬製品の機械的試験である。薬物製品を経鼻乱用(吹送)に好適な粒径にすりつぶす目的で、市販のコーヒーグラインダー(Mr. Coffee)を模すためにRetsch Knife Mill GRINDOMIX GM200(TE96)を利用した。500マイクロメートル(μm)粒径ふるい(35メッシュ)を利用するATM L3P Sonic Sifter(TE47)を利用して、粒径解析を実施した。本研究の目的のためには、直径500μm未満の粒子は全て経鼻乱用に好適であるとみなされる。直径500μm超の粒子は全て鼻腔の血管により十分に吸収されないことが一般的に受容されている。
Claims (25)
- (a)乱用されやすい活性物質、
(b)約30,000ダルトン〜約40,000ダルトンの間の平均分子量を有する第1のポリエチレングリコール(PEG)、及び
(c)約3000ダルトン〜約4000ダルトンの間の平均分子量を有する第2のPEG
を含む即時放出性乱用抑止性カプセル剤であって、
第1のPEG対第2のPEGの比が約1:4w/w未満である、即時放出性乱用抑止性カプセル剤。 - 第1のPEG及び第2のPEGが、合わせて剤形の少なくとも約60wt%である、請求項1に記載のカプセル剤。
- 内容物の少なくとも80%が水及びアルコールの両方に可溶である、請求項1に記載のカプセル剤。
- 活性物質が酒石酸水素ヒドロコドンである、請求項1に記載のカプセル剤。
- 活性物質がオキシコドンHClである、請求項1に記載のカプセル剤。
- FD&C青色1号、FD&C黄色6号及びFD&C赤色40号を含む灰色染料をさらに含む、請求項1に記載のカプセル剤。
- 染料が乱用に対する視覚的抑止性をもたらす、請求項6に記載のカプセル剤。
- 第1のPEG対第2のPEGの比が約1:7w/w〜約1:11w/wの間である、請求項1に記載のカプセル剤。
- 第1のPEGが約35,000ダルトンの平均分子量を有し、第2のPEGが約3350ダルトンの平均分子量を有する、請求項1に記載のカプセル剤。
- カプセル剤が少なくとも約2.5wt%の活性物質を含む、請求項1に記載のカプセル剤。
- カプセル剤が、活性物質、第1のPEG及び第2のPEGを含む加熱均質化懸濁液でカプセルボディを充填することにより調製される、請求項1に記載のカプセル剤。
- (a)乱用されやすい活性物質、及び
(b)約6200ダルトン〜約7800ダルトンの間の重量平均分子量を有するPEG
を含む即時放出性乱用抑止性カプセル剤。 - カプセル剤が、少なくとも約60wt%のPEGを含む、請求項12に記載のカプセル剤。
- 活性物質が酒石酸水素ヒドロコドンである、請求項12に記載のカプセル剤。
- 活性物質がオキシコドンHClである、請求項12に記載のカプセル剤。
- (a)乱用されやすい活性物質、
(b)約60℃以上の融点を有する第1のPEG、及び
(c)約57℃以下の融点を有する第2のPEG
を含む即時放出性乱用抑止性カプセル剤であって、
カプセルの内容物が40℃/相対湿度75%で固体であり、投与又は溶出試験後45分以内に活性成分の少なくとも75%がカプセルから放出される、即時放出性乱用抑止性カプセル剤。 - 第1のPEG及び第2のPEGが、合わせてカプセル剤の少なくとも約60wt%である、請求項16に記載のカプセル剤。
- 活性物質が酒石酸水素ヒドロコドンである、請求項16に記載のカプセル剤。
- 活性物質がオキシコドンHClである、請求項16に記載のカプセル剤。
- 少なくとも1種の乱用されやすい活性物質を含む即時放出性乱用抑止性カプセル剤の製造方法であって、
(a)(i)少なくとも1種の乱用されやすい活性物質、
(ii)約30,000ダルトン〜約40,000ダルトンの間の平均分子量を有する第1のPEG、及び
(iii)約3000ダルトン〜約4000ダルトンの間の平均分子量を有する第2のPEG
の均質化懸濁液を調製するステップ、並びに
(b)均質化懸濁液をカプセルボディに充填してカプセル剤を製造するステップ
を含み、
第1のPEG対第2のPEGの比が約1:4w/w未満である、方法。 - 第1のPEG及び第2のPEGが、合わせてカプセル剤の少なくとも約60wt%である、請求項20に記載の方法。
- 活性物質が酒石酸水素ヒドロコドンである、請求項20に記載の方法。
- 活性物質がオキシコドンHClである、請求項20に記載の方法。
- カプセル剤が、カプセルボディをカプセルキャップと接合させることにより形成される、請求項20に記載の方法。
- 治療有効量の請求項1に記載のカプセル剤を、それを必要とする対象に投与するステップを含む、痛みを治療する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462025878P | 2014-07-17 | 2014-07-17 | |
US62/025,878 | 2014-07-17 | ||
PCT/US2015/039336 WO2016010771A1 (en) | 2014-07-17 | 2015-07-07 | Immediate release abuse deterrent liquid fill dosage form |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018131927A Division JP2018197241A (ja) | 2014-07-17 | 2018-07-12 | 即時放出性乱用抑止性液体充填剤形 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017521448A true JP2017521448A (ja) | 2017-08-03 |
JP6371463B2 JP6371463B2 (ja) | 2018-08-08 |
Family
ID=55073631
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017502652A Expired - Fee Related JP6371463B2 (ja) | 2014-07-17 | 2015-07-07 | 即時放出性乱用抑止性液体充填剤形 |
JP2018131927A Pending JP2018197241A (ja) | 2014-07-17 | 2018-07-12 | 即時放出性乱用抑止性液体充填剤形 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018131927A Pending JP2018197241A (ja) | 2014-07-17 | 2018-07-12 | 即時放出性乱用抑止性液体充填剤形 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9707184B2 (ja) |
EP (1) | EP3169315B1 (ja) |
JP (2) | JP6371463B2 (ja) |
AU (2) | AU2015290098B2 (ja) |
CA (1) | CA2955229C (ja) |
DK (1) | DK3169315T3 (ja) |
ES (1) | ES2809458T3 (ja) |
WO (1) | WO2016010771A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015336065A1 (en) * | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523833A (ja) * | 2006-01-21 | 2009-06-25 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 乱用薬剤送達のための製剤および方法 |
US20100204259A1 (en) * | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
JP2013537915A (ja) * | 2010-09-24 | 2013-10-07 | キューアールエックスファーマ リミテッド | オピオイドの制御放出製剤 |
US20140010873A1 (en) * | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
Family Cites Families (692)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB135381A (ja) | ||||
CA265145A (en) | 1926-10-19 | T. Thomas Horace | Transmission brake | |
CA264736A (en) | 1926-10-05 | S. Goulet William | Rotary engine | |
CA265559A (en) | 1926-11-02 | F. L. Smidth And Co. | Tube mill | |
NL143131B (nl) | 1964-07-11 | 1974-09-16 | Acf Chemiefarma Nv | Werkwijze voor de bereiding van antiparasitair werkzame preparaten en van actieve bestanddelen daarvoor alsmede de aldus verkregen gevormde preparaten. |
CS162957B1 (ja) | 1972-05-24 | 1975-07-31 | ||
US4126684A (en) | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
GB1572226A (en) | 1977-11-03 | 1980-07-30 | Hoechst Uk Ltd | Pharmaceutical preparations in solid unit dosage form |
JPS5584166A (en) | 1978-12-20 | 1980-06-25 | Lion Hamigaki Kk | Band for spongy medicine |
US4507276A (en) | 1982-08-20 | 1985-03-26 | Bristol-Myers Company | Analgesic capsule |
PL133984B2 (en) | 1983-02-21 | 1985-07-31 | Method of manufacture of complex of derivatives of cellulose with polyhydric alcohol or its polymer | |
JPS6092214A (ja) | 1983-10-26 | 1985-05-23 | Ss Pharmaceut Co Ltd | 軟カプセル充填用組成物 |
NL8520012A (nl) | 1984-02-08 | 1986-01-02 | Scherer Corp R P | Aceetaminofeen gelatinecapsule, die snelle aanvang van therapeutische activiteit na orale toediening oplevert. |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US5155212A (en) | 1986-05-21 | 1992-10-13 | Abbott Laboratories | Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit |
US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
GB8926612D0 (en) * | 1989-11-24 | 1990-01-17 | Erba Farmitalia | Pharmaceutical compositions |
US5141961A (en) | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
EP0662840A1 (en) | 1992-10-09 | 1995-07-19 | The Procter & Gamble Company | Pharmaceutical compositions and methods for treating cold symptoms |
WO1994018970A1 (en) | 1993-02-18 | 1994-09-01 | Warner-Lambert Company | Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents |
IL108366A (en) | 1993-03-11 | 1999-11-30 | Taro Vit Ind Ltd | Semi-solid pharmaceutical compounds and a device for their use |
SE9301057L (sv) | 1993-03-30 | 1994-10-01 | Pharmacia Ab | Beredning med kontrollerad frisättning |
US5431916A (en) | 1993-04-29 | 1995-07-11 | The Procter & Gamble Company | Pharmaceutical compositions and process of manufacture thereof |
EP0695175A1 (en) | 1993-04-30 | 1996-02-07 | The Procter & Gamble Company | Coated pharmaceutical compositions |
WO1994026731A1 (en) | 1993-05-13 | 1994-11-24 | Merck Frosst Canada Inc. | 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase |
JPH1133084A (ja) | 1994-02-10 | 1999-02-09 | Yamanouchi Pharmaceut Co Ltd | 口腔内溶解型錠剤およびその製造方法 |
US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5660859A (en) | 1994-12-29 | 1997-08-26 | Mcneil-Ppc, Inc. | Gelling agent for polyethylene glycol |
US5616621A (en) | 1995-01-30 | 1997-04-01 | American Home Products Corporation | Taste masking liquids |
US5840731A (en) | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
EA199800535A1 (ru) | 1995-12-07 | 1998-12-24 | Эли Лилли Энд Компани | Способ лечения боли |
KR19990071976A (ko) | 1995-12-07 | 1999-09-27 | 피터 지. 스트링거 | 통증 치료용 조성물 |
KR100341829B1 (ko) | 1996-03-08 | 2002-08-22 | 니코메드 덴마크 에이/에스 | 방출특성이변형된다-유니트투여량조성물 |
DE69709646T2 (de) | 1996-03-12 | 2002-08-14 | Alza Corp | Zusammensetzung und dosisform mit einem opioid-antagonisten |
AU3404997A (en) | 1996-05-31 | 1998-01-05 | Euro-Celtique S.A. | Sustained release oxycodone formulations with no fed/fast effect |
WO1997049384A1 (en) | 1996-06-26 | 1997-12-31 | Board Of Regents, The University Of Texas System | Hot-melt extrudable pharmaceutical formulation |
US6024980A (en) | 1996-06-28 | 2000-02-15 | Mcneil-Ppc, Inc. | Multiphase soft gelatin dosage form |
US5914129A (en) | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
AU744156B2 (en) | 1996-10-28 | 2002-02-14 | General Mills Inc. | Embedding and encapsulation of controlled release particles |
DE19651551C2 (de) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
US6160020A (en) | 1996-12-20 | 2000-12-12 | Mcneill-Ppc, Inc. | Alkali metal and alkaline-earth metal salts of acetaminophen |
HUP9903375A3 (en) | 1997-03-24 | 2000-04-28 | Lilly Co Eli | Synergistic pharmaceutical compositions containing olanzapine and analgetic drugs |
AU7472798A (en) | 1997-05-07 | 1998-11-27 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
CA2289190A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
US20040043071A1 (en) | 2002-06-21 | 2004-03-04 | Pauletti Giovanni M. | Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs |
US7744916B2 (en) | 1997-06-11 | 2010-06-29 | Umd, Inc. | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs |
AU7696098A (en) | 1997-08-11 | 1999-03-01 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
RS49982B (sr) | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US20030185761A1 (en) | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
EP2266564B1 (en) | 1997-12-22 | 2013-03-13 | Euro-Celtique S.A. | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist |
WO1999032120A1 (en) | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | A method of preventing abuse of opioid dosage forms |
US6251430B1 (en) | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
JP2002502908A (ja) | 1998-02-06 | 2002-01-29 | ユニオン・カーバイド・ケミカルズ・アンド・プラスティックス・テクノロジー・コーポレイション | アルキレンオキシドポリマー組成物 |
US6245357B1 (en) | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
PE20000601A1 (es) | 1998-03-23 | 2000-07-25 | Gen Mills Inc | Encapsulado de componentes en productos comestibles |
US6054451A (en) | 1998-04-21 | 2000-04-25 | Algos Pharmaceutical Corporation | Analgesic composition and method for alleviating pain |
PT1119345E (pt) | 1998-10-09 | 2009-07-27 | Gen Mills Inc | Encapsulação de componentes líquidos sensíveis numa matriz para obter partículas discretas de longa conservação |
US20060240105A1 (en) | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
AU1398899A (en) | 1998-11-12 | 2000-06-05 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with centrally acting analgesics |
CA2351224A1 (en) | 1998-11-12 | 2000-05-25 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
FR2787715B1 (fr) | 1998-12-23 | 2002-05-10 | Synthelabo | Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
IT1311923B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1311924B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
US6500459B1 (en) | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
MXPA02000725A (es) | 1999-07-29 | 2003-07-14 | Roxane Lab Inc | Formulacion opioide de liberacion sostenida. |
IT1313579B1 (it) | 1999-07-30 | 2002-09-09 | Acraf | Composizione farmaceutica liquida a base di paracetamolo. |
IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
ES2226886T3 (es) | 1999-08-31 | 2005-04-01 | Grunenthal Gmbh | Forma de administracion de accion retardada que contiene sacarinato de tramadol. |
US6432450B1 (en) | 1999-09-09 | 2002-08-13 | Gerhard Gergely | Effervescent granules with delayed effervescent effect |
US6264983B1 (en) | 1999-09-16 | 2001-07-24 | Rhodia, Inc. | Directly compressible, ultra fine acetaminophen compositions and process for producing same |
US6572891B1 (en) | 1999-10-23 | 2003-06-03 | Alkaloid Ad | Sublingual oral dosage form |
DE60022776T2 (de) | 1999-10-29 | 2006-08-24 | Childrens Hospital Los Angeles, Los Angeles | Verfahren und material zur hämostase bei knochen |
AU1466001A (en) | 1999-11-05 | 2001-05-14 | Phase-1 Molecular Toxicology | Methods of determining individual hypersensitivity to an agent |
US20050233459A1 (en) | 2003-11-26 | 2005-10-20 | Melker Richard J | Marker detection method and apparatus to monitor drug compliance |
US6207674B1 (en) | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
US6608041B2 (en) | 2000-02-18 | 2003-08-19 | Milton Hammerly | Analgesics combined with naturally-occurring chondroprotective agents |
US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
EP1280529A2 (en) | 2000-05-05 | 2003-02-05 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists |
AU5945801A (en) | 2000-05-05 | 2001-11-20 | Pain Therapeutics Inc | Opoid antagonist compositions and dosage forms |
US20040156872A1 (en) | 2000-05-18 | 2004-08-12 | Elan Pharma International Ltd. | Novel nimesulide compositions |
AU2001264570A1 (en) | 2000-05-31 | 2001-12-11 | Warner Lambert Company | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
GB0015617D0 (en) | 2000-06-26 | 2000-08-16 | Vectura Ltd | Improved preparations for dermal delivery of active substances |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
US20040047910A1 (en) | 2000-07-07 | 2004-03-11 | Christian Beckett | Suppository and composition comprising at least one polyethylene glycol |
CA2386794A1 (en) | 2000-07-13 | 2002-01-24 | Euro-Celtique, S.A. | Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
WO2002051432A1 (en) | 2001-11-16 | 2002-07-04 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
WO2003020200A2 (en) | 2000-11-16 | 2003-03-13 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
US6924273B2 (en) | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
IL139177A0 (en) | 2000-10-20 | 2001-11-25 | S C Republic Dev S R L | Sustained release drug delivery system |
EP2932964A1 (en) | 2000-10-30 | 2015-10-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US6800668B1 (en) | 2001-01-19 | 2004-10-05 | Intellipharmaceutics Corp. | Syntactic deformable foam compositions and methods for making |
US6869618B2 (en) | 2001-04-10 | 2005-03-22 | Kiel Laboratories, Inc. | Process for preparing tannate liquid and semi-solid dosage forms |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
JP2005515960A (ja) | 2001-05-11 | 2005-06-02 | エンドー ファーマシューティカルズ, インコーポレイティド | 乱用耐性のオピオイド投薬形態 |
JP2004534056A (ja) | 2001-06-08 | 2004-11-11 | エンドー ファーマシューティカルズ, インコーポレイティド | アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス |
JP2004537525A (ja) | 2001-06-11 | 2004-12-16 | メルク エンド カムパニー インコーポレーテッド | PPARδアゴニストの投与による炎症性疾患の治療法 |
WO2003002100A1 (en) | 2001-06-26 | 2003-01-09 | Farrell John J | Tamper-proof narcotic delivery system |
US20030021841A1 (en) | 2001-07-02 | 2003-01-30 | Matharu Amol Singh | Pharmaceutical composition |
DK1416842T3 (da) | 2001-07-18 | 2009-03-16 | Euro Celtique Sa | Farmaceutiske kombinationer af oxycodon og naloxon |
WO2003013481A1 (en) | 2001-08-03 | 2003-02-20 | Bakulesh Mafatlal Khamar | The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients |
US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
AU2002321879A1 (en) | 2001-08-06 | 2003-03-03 | Thomas Gruber | Pharmaceutical formulation containing dye |
US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030068276A1 (en) | 2001-09-17 | 2003-04-10 | Lyn Hughes | Dosage forms |
US20030092724A1 (en) | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
EP1429730A4 (en) | 2001-09-26 | 2010-06-16 | Penwest Pharmaceuticals Compan | OPIOID FORMULATIONS WITH REDUCED ABUSE POTENTIAL |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
KR100974842B1 (ko) | 2001-10-18 | 2010-08-11 | 넥타르 테라퓨틱스 | 아편양 길항제의 중합체 공액 |
CN1571661A (zh) | 2001-10-22 | 2005-01-26 | 塔罗制药工业有限公司 | 遮味抗溢出制剂 |
US20050143471A1 (en) | 2001-10-22 | 2005-06-30 | Shen Gao | Taste masking spill-resistant formulation |
US20030235618A1 (en) | 2001-10-22 | 2003-12-25 | Taro Pharmaceutical Industries Ltd. | Taste masking spill-resistant formulation |
US6771370B2 (en) | 2001-10-22 | 2004-08-03 | The Texas A&M University System | Characterizing powders using frequency-domain photon migration |
CA2464528A1 (en) | 2001-11-02 | 2003-05-15 | Elan Corporation, Plc | Pharmaceutical composition |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
EP1458718B1 (en) | 2001-12-14 | 2006-10-25 | Merck Frosst Canada Ltd. | Quinolinones as prostaglandin receptor ligands |
US6713470B2 (en) | 2002-01-22 | 2004-03-30 | Ml Laboratories Plc | Method of treatment |
US20070167853A1 (en) | 2002-01-22 | 2007-07-19 | Melker Richard J | System and method for monitoring health using exhaled breath |
KR100540035B1 (ko) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
JP2005519923A (ja) | 2002-02-04 | 2005-07-07 | ファルマシア・コーポレーション | シクロオキシゲナーゼ−2選択的阻害剤ならびに風邪および咳止め薬の組み合わせを用いる風邪および咳の治療ならびにそれらの組成物 |
DK1480624T3 (da) | 2002-02-07 | 2007-03-12 | Pharmacia Corp | Farmaceutisk tablet |
KR100666520B1 (ko) | 2002-02-07 | 2007-01-11 | 파마시아 코포레이션 | 점막 송달을 위한 약제학적 투약형 |
GB0203276D0 (en) | 2002-02-12 | 2002-03-27 | Novartis Ag | Organic compounds |
US20060177381A1 (en) | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
EP1476139B1 (en) | 2002-02-21 | 2017-05-17 | Valeant Pharmaceuticals Luxembourg S.à.r.l. | Controlled release dosage forms |
EP1490090A4 (en) | 2002-02-22 | 2006-09-20 | New River Pharmaceuticals Inc | SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS |
US6753009B2 (en) | 2002-03-13 | 2004-06-22 | Mcneil-Ppc, Inc. | Soft tablet containing high molecular weight polyethylene oxide |
SI1578350T1 (sl) | 2002-03-26 | 2009-10-31 | Euro Celtique Sa | Z gelom obloženi sestavki z zadržanim sproščanjem |
DE10215067A1 (de) | 2002-04-05 | 2003-10-16 | Euro Celtique Sa | Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst |
DE10215131A1 (de) | 2002-04-05 | 2003-10-16 | Euro Celtique Sa | Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen |
NZ535286A (en) | 2002-04-05 | 2007-07-27 | Euro Celtique Sa | Matrix for sustained, invariant and independent release of active compounds |
US20030191147A1 (en) | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
WO2003088991A1 (en) | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
US20030199439A1 (en) | 2002-04-22 | 2003-10-23 | Simon David Lew | Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics |
US20030199496A1 (en) | 2002-04-22 | 2003-10-23 | Simon David Lew | Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use |
FR2838647B1 (fr) | 2002-04-23 | 2006-02-17 | Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant | |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20040009172A1 (en) | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20030203027A1 (en) | 2002-04-26 | 2003-10-30 | Ethicon, Inc. | Coating technique for deposition of drug substance on a substrate |
US20050106249A1 (en) | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
JP2005525405A (ja) | 2002-04-29 | 2005-08-25 | アルザ・コーポレーシヨン | オキシコドンを制御して補給する方法および剤型 |
US7485298B2 (en) | 2002-05-23 | 2009-02-03 | Michael Powell | Diagnosis and treatment of human dormancy-related sequellae |
KR20050034645A (ko) | 2002-05-31 | 2005-04-14 | 알자 코포레이션 | 다양한 용량의 옥시코돈을 삼투 전달하기 위한 제형 및조성물 |
US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
EP1542658B1 (en) | 2002-08-15 | 2010-12-29 | Euro-Celtique S.A. | Pharmaceutical compositions comprising an opioid analgesic |
US20050152905A1 (en) | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
CA2498798A1 (en) | 2002-09-20 | 2004-04-01 | Alpharma, Inc. | Sustained-release opioid formulations and methods of use |
CA2499994C (en) | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
US20040062778A1 (en) | 2002-09-26 | 2004-04-01 | Adi Shefer | Surface dissolution and/or bulk erosion controlled release compositions and devices |
EP1578719A4 (en) | 2002-10-25 | 2006-07-05 | Collegium Pharmaceutical Inc | P-HYDROXY-MILNACIPRAN STEREOISOMERS AND METHODS OF USING THE SAME |
US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
EP1603593A4 (en) | 2002-11-15 | 2007-08-01 | Branded Products For The Futur | PHARMACEUTICAL COMPOSITION |
US20040110781A1 (en) | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
ES2350689T3 (es) | 2002-12-13 | 2011-01-26 | Durect Corporation | Sistema de suministro de fármacos oral que comprende materiales vehículo líquidos de alta viscosidad. |
EP1572164A2 (en) | 2002-12-18 | 2005-09-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
ES2645930T3 (es) | 2003-01-03 | 2017-12-11 | Supernus Pharmaceuticals, Inc. | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas |
US7763043B2 (en) | 2003-01-09 | 2010-07-27 | Boston Scientific Scimed, Inc. | Dilatation catheter with enhanced distal end for crossing occluded lesions |
US20040259948A1 (en) | 2003-01-10 | 2004-12-23 | Peter Tontonoz | Reciprocal regulation of inflammation and lipid metabolism by liver X receptors |
WO2004064832A2 (en) | 2003-01-22 | 2004-08-05 | Pfizer Products Inc. | Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist |
CA2509259A1 (en) | 2003-01-23 | 2004-08-05 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
FR2850576B1 (fr) | 2003-02-05 | 2007-03-23 | Ethypharm Sa | Composition comprenant un melange de principes actifs, et procede de preparation |
EP1605916A4 (en) | 2003-02-12 | 2012-02-22 | R & P Korea Co Ltd | SOLUBENT SOLVENT SYSTEM WITH SOLUBLE PEEL WITH IMPROVED ELUTION RATE |
US20060178354A1 (en) | 2003-02-27 | 2006-08-10 | Lucas John M | Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof |
MXPA05009978A (es) | 2003-03-20 | 2005-11-04 | Pharmacia Corp | Formulacion dispersable de un agente antiinflamatorio. |
US20050004098A1 (en) | 2003-03-20 | 2005-01-06 | Britten Nancy Jean | Dispersible formulation of an anti-inflammatory agent |
ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
CA2524806C (en) | 2003-05-07 | 2011-07-12 | Akina, Inc. | Highly plastic granules for making fast melting tablets |
US8906413B2 (en) | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
US8029822B2 (en) | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
JPWO2004108163A1 (ja) | 2003-06-04 | 2006-07-20 | 塩野義製薬株式会社 | 低帯電性粉末の製造方法 |
US20060240037A1 (en) | 2003-06-04 | 2006-10-26 | Edward Fey | Methods and compositions for the treatment and prevention of degenerative joint disorders |
US20040265378A1 (en) | 2003-06-25 | 2004-12-30 | Yingxu Peng | Method and compositions for producing granules containing high concentrations of biologically active substances |
US20060165790A1 (en) | 2003-06-27 | 2006-07-27 | Malcolm Walden | Multiparticulates |
TWI357815B (en) | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
CA2530843A1 (en) | 2003-07-01 | 2005-01-20 | Todd Maibach | Film comprising therapeutic agents |
WO2005002597A1 (en) | 2003-07-02 | 2005-01-13 | Polycord, Inc. | Method for delivering polymerized therapeutic agent compositions and compositions thereof |
JP5296314B2 (ja) | 2003-07-17 | 2013-09-25 | バナー ファーマキャップス,インコーポレイティド | 制御放出製剤 |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US20050059023A1 (en) | 2003-09-16 | 2005-03-17 | Cantor Thomas L. | Methods and kits for monitoring resistance to therapeutic agents |
WO2005028539A2 (en) | 2003-09-17 | 2005-03-31 | Nektar Therapeutics Al, Corporation | Multi-arm polymer prodrugs |
ES2344350T3 (es) | 2003-09-25 | 2010-08-25 | Euro-Celtique S.A. | Combinaciones farmaceuticas de hidrocodona y naltrexona. |
PL1663229T3 (pl) | 2003-09-25 | 2010-09-30 | Euro Celtique Sa | Farmaceutyczne kombinacje hydrokodonu i naltreksonu |
US20080031901A1 (en) | 2004-09-24 | 2008-02-07 | Abbott Laboratories | Sustained release monoeximic formulations of opioid and nonopioid analgesics |
CA2540056C (en) | 2003-09-26 | 2015-03-24 | Alza Corporation | Controlled release formulations of opioid and nonopioid analgesics |
US20070259033A1 (en) | 2003-09-26 | 2007-11-08 | Evangeline Cruz | Controlled release formulations exhibiting an ascending rate of release |
BRPI0414876A (pt) | 2003-09-30 | 2006-11-21 | New River Pharmaceuticals Inc | compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos |
WO2005038049A2 (en) | 2003-10-06 | 2005-04-28 | Heinrich Guenther | System and method for optimizing drug therapy |
US20060009478A1 (en) | 2003-10-15 | 2006-01-12 | Nadav Friedmann | Methods for the treatment of back pain |
US20050245557A1 (en) | 2003-10-15 | 2005-11-03 | Pain Therapeutics, Inc. | Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain |
JP2007509155A (ja) | 2003-10-21 | 2007-04-12 | アルファーマ インコーポレイテッド | クエチアピンを含有する薬剤 |
AU2003303744A1 (en) | 2003-10-31 | 2005-06-17 | Elan Pharma International Ltd. | Novel nimesulide compositions |
EP1684732A2 (en) | 2003-11-12 | 2006-08-02 | Ranbaxy Laboratories Limited | Ibuprofen-containing soft gelatin capsules |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
DE602004028155D1 (de) | 2003-12-16 | 2010-08-26 | United Therapeutics Corp | Verwendung von treprostinil zur behandlung von ischämischen läsionen |
US20090124697A1 (en) | 2003-12-16 | 2009-05-14 | United Therapeutics Corporation | Inhalation formulations of treprostinil |
US20050266032A1 (en) | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
WO2005063219A2 (en) | 2003-12-23 | 2005-07-14 | Ranbaxy Laboratories Limited | Ibuprofen-containing soft gelatin capsules |
AU2004308973A1 (en) | 2003-12-23 | 2005-07-14 | Alza Corporation | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
NZ589967A (en) | 2004-01-14 | 2012-07-27 | Gilead Sciences Inc | Lipid-based dispersions useful for drug delivery |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
WO2005092306A1 (en) | 2004-03-11 | 2005-10-06 | The General Hospital Corporation | Methods and compositions for modulating opioid tolerance and chronic pain |
US20070042969A1 (en) | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
ES2244326B1 (es) | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de substancias activas. |
US20050226929A1 (en) | 2004-04-12 | 2005-10-13 | Jianbo Xie | Controlled release opioid analgesic formulation |
GB0408308D0 (en) | 2004-04-14 | 2004-05-19 | Vectura Ltd | Pharmaceutical compositions |
BRPI0510043A (pt) | 2004-04-20 | 2007-10-16 | Pfizer | método de tratamento de dor neuropática usando antagonista de receptor crth2 |
GB0408854D0 (en) | 2004-04-21 | 2004-05-26 | Univ York | Separating method |
WO2005107467A2 (en) | 2004-05-03 | 2005-11-17 | Descartes Therapeutics, Inc. | Compositions including opioids and methods of their use in treating pain |
US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
US20050265955A1 (en) | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
US20080317849A1 (en) | 2004-06-17 | 2008-12-25 | Stephan Christgau | Method for Improving the Medical Treatment of Pain |
CA2570389A1 (en) | 2004-06-17 | 2005-12-29 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
WO2006017159A1 (en) | 2004-07-09 | 2006-02-16 | Drugtech Corporation | Controlled phase composition technology as an improved process for protection of drugs |
US20060039865A1 (en) | 2004-07-26 | 2006-02-23 | Preston David M | Pharmaceutical compositions and methods for the prevention of drug misuse |
US20060024368A1 (en) | 2004-07-30 | 2006-02-02 | Reza Fassihi | Compressed composite delivery system for release-rate modulation of bioactives |
US20070003622A1 (en) | 2004-12-16 | 2007-01-04 | Sovereign Pharmaceuticals, Ltd. | Diphenhydramine containing dosage form |
US8039456B2 (en) | 2004-08-12 | 2011-10-18 | Helsinn Therapeutics (U.S.), Inc. | Method of stimulating the motility of the gastrointestinal system using ipamorelin |
AU2005272598B2 (en) | 2004-08-12 | 2011-11-17 | Helsinn Therapeutics (U.S.), Inc. | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
EP1789028A2 (en) | 2004-08-24 | 2007-05-30 | Neuromolecular Pharmaceuticals Inc | Compositions for treating nociceptive pain |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
WO2006030402A2 (en) | 2004-09-17 | 2006-03-23 | Ranbaxy Laboratories Limited | Dual compartment osmotic delivery device |
US20060062734A1 (en) | 2004-09-20 | 2006-03-23 | Melker Richard J | Methods and systems for preventing diversion of prescription drugs |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
US20060067971A1 (en) | 2004-09-27 | 2006-03-30 | Story Brooks J | Bone void filler |
US20060074422A1 (en) | 2004-09-27 | 2006-04-06 | Story Brooks J | Suture anchor and void filler combination |
CA2582096C (en) | 2004-10-01 | 2014-01-07 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
EP1804751A2 (en) | 2004-10-04 | 2007-07-11 | QLT USA, Inc. | Ocular delivery of polymeric delivery formulations |
WO2006044645A2 (en) | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
WO2006046114A2 (en) | 2004-10-25 | 2006-05-04 | Ranbaxy Laboratories Limited | Osmotic dosage forms providing ascending drug release, and processes for their preparation |
US20060142241A1 (en) | 2004-11-01 | 2006-06-29 | Yoo Seo H | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
US20060099254A1 (en) | 2004-11-02 | 2006-05-11 | Desai Divyakant S | Sustained release drug delivery system and method |
JP2006150061A (ja) | 2004-11-04 | 2006-06-15 | Nec Corp | ドラッグデリバリシステム及びそれに用いる薬剤カプセル並びに送信機 |
BRPI0518322A2 (pt) | 2004-11-16 | 2008-11-18 | Limerick Neurosciences Inc | composiÇço, kit, e, mÉtodos para tratar uma condiÇço, para reverter um efeito no sistema nervoso central de um agente, para tratar um animal de dor, e para controlar dor crânica |
US20070087977A1 (en) | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
FR2878161B1 (fr) | 2004-11-23 | 2008-10-31 | Flamel Technologies Sa | Forme medicamenteuse orale, solide et concue pour eviter le mesusage |
US20060110327A1 (en) | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20070231268A1 (en) | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
FR2878158B1 (fr) | 2004-11-24 | 2009-01-16 | Flamel Technologies Sa | Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage |
US20060177380A1 (en) | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US8574626B2 (en) | 2004-12-03 | 2013-11-05 | Osmotica Kereskedelmi és Szolgáltató KFT | Osmotic device containing amantadine and an osmotic salt |
AU2005319367B2 (en) | 2004-12-20 | 2012-05-24 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
WO2006075125A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | GnRH ANALOGUE FORMULATIONS |
US9757461B2 (en) | 2005-01-14 | 2017-09-12 | Camurus Ab | GnRH analogue formulations |
FR2881652B1 (fr) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
AU2006212021B2 (en) | 2005-02-10 | 2010-09-30 | Orexo Ab | Pharmaceutical compositions useful in the transmucosal administration of drugs |
US20090111837A1 (en) | 2005-03-01 | 2009-04-30 | Peter Cox | Use of pde7 inhibitors for the treatment of neuropathic pain |
US20060205752A1 (en) | 2005-03-14 | 2006-09-14 | Keith Whitehead | Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid |
US20060210613A1 (en) | 2005-03-15 | 2006-09-21 | Carliss Richard D | Therapeutic wound care product |
FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
US9149439B2 (en) | 2005-03-21 | 2015-10-06 | Sandoz Ag | Multi-particulate, modified-release composition |
CN101151021A (zh) | 2005-03-28 | 2008-03-26 | 奥瑞克索股份公司 | 用于疼痛治疗的新药物组合物 |
US20090117054A1 (en) | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
WO2006103551A1 (en) | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Controlled release formulations of oxycodone |
GB0506982D0 (en) * | 2005-04-06 | 2005-05-11 | Mw Encap Ltd | Abuse resistant capsules |
WO2006116148A2 (en) | 2005-04-22 | 2006-11-02 | Wyeth | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
CA2607624A1 (en) | 2005-05-10 | 2006-11-16 | Novartis Ag | Extrusion process for making compositions with poorly compressible therapeutic compounds |
US20060263429A1 (en) | 2005-05-20 | 2006-11-23 | Hengsheng Feng | Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof |
US20090143761A1 (en) | 2005-06-03 | 2009-06-04 | Transdermal Patents Company, Llc | Agent delivery system and uses of same |
US20060292214A1 (en) | 2005-06-03 | 2006-12-28 | Elan Pharma International Limited | Nanoparticulate acetaminophen formulations |
WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
JP2008543851A (ja) | 2005-06-13 | 2008-12-04 | ポール・ローゼンバーグ | 催吐剤封入カプセル |
US9060950B2 (en) | 2005-06-13 | 2015-06-23 | Paul H. Rosenberg, Proximate Concepts, LLC. | Emetic embedded capsule |
US20070020339A1 (en) | 2005-07-20 | 2007-01-25 | Pharmorx Inc. | Compositions and methods for controlling abuse of medications |
WO2007021970A2 (en) | 2005-08-15 | 2007-02-22 | Praecis Pharmaceuticals, Inc. | Stable pharmaceutical formulations and methods of use thereof |
KR20080047571A (ko) | 2005-08-26 | 2008-05-29 | 비피에스아이 홀딩스, 엘엘씨. | 방출 조절 하이프로멜로스 매트릭스를 포함하는 약학조성물 |
US8343546B2 (en) | 2005-09-13 | 2013-01-01 | Coating Place, Inc. | Ion exchange resin treated to control swelling |
KR100708713B1 (ko) | 2005-09-24 | 2007-04-17 | 삼성에스디아이 주식회사 | 나노복합체, 나노복합 전해질막 및 이를 이용한 연료전지 |
FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
WO2007050631A2 (en) | 2005-10-25 | 2007-05-03 | Cima Labs Inc. | Dosage form with coated active |
CA2627292C (en) | 2005-10-26 | 2012-04-17 | Banner Pharmacaps, Inc. | Hydrophilic vehicle-based dual controlled release matrix system |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
WO2007056142A2 (en) | 2005-11-02 | 2007-05-18 | Theraquest Biosciences, Llc | Methods of preventing the serotonin syndrome and compositions for use therefor |
US20090082466A1 (en) | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
US7544676B2 (en) | 2005-11-10 | 2009-06-09 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
FR2892937B1 (fr) | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
WO2007132293A2 (en) | 2005-11-10 | 2007-11-22 | Circ Pharma Research And Development Limited | Once-daily administration of central nervous system drugs |
US20070134493A1 (en) | 2005-12-08 | 2007-06-14 | Kanji Meghpara | Compositions and capsules with stable hydrophilic layers |
CA2629046C (en) | 2005-12-13 | 2014-04-08 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
WO2007072503A2 (en) | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
TW200734334A (en) | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
US20090317355A1 (en) | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
US20100172989A1 (en) | 2006-01-21 | 2010-07-08 | Abbott Laboratories | Abuse resistant melt extruded formulation having reduced alcohol interaction |
US20090022798A1 (en) | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
EP1813276A1 (en) | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
BRPI0707325A2 (pt) | 2006-01-27 | 2011-05-03 | Eurand Inc | formulação de dosagem de liberação multiparticulada e método para preparação da mesma |
US7520888B2 (en) | 2006-02-14 | 2009-04-21 | Warsaw Orthopedic, Inc. | Treatment of the vertebral column |
US20070213717A1 (en) | 2006-02-14 | 2007-09-13 | Sdgi Holdings, Inc. | Biological fusion in the vertebral column |
GB0603008D0 (en) | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
US20070213718A1 (en) | 2006-02-14 | 2007-09-13 | Sdgi Holdings, Inc. | Treatment of the vertebral column |
FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
US8940796B2 (en) | 2006-02-21 | 2015-01-27 | Wyeth Llc | Phenylephrine liquid formulations |
FR2898056B1 (fr) | 2006-03-01 | 2012-01-20 | Ethypharm Sa | Comprimes resistant a l'ecrasement destines a eviter le detournement illicite |
CN101460060A (zh) | 2006-03-01 | 2009-06-17 | 特莱斯特拉塔公司 | 局部治疗焦油响应性皮肤病用的组合物和方法 |
JP5349059B2 (ja) | 2006-03-06 | 2013-11-20 | ポーゼン インコーポレイテッド | 薬物の組み合わせを投与するための剤形 |
US9265732B2 (en) | 2006-03-06 | 2016-02-23 | Pozen Inc. | Dosage forms for administering combinations of drugs |
US20070212417A1 (en) | 2006-03-07 | 2007-09-13 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
US20080069889A1 (en) | 2006-03-07 | 2008-03-20 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
EP1993519A4 (en) | 2006-03-15 | 2011-12-21 | Acura Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR PREVENTING THE ABUSE OF ORGANIC PRODUCTS MANIPULATED ORAL |
CN102488652B (zh) | 2006-03-16 | 2014-06-18 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
JP5457830B2 (ja) | 2006-04-03 | 2014-04-02 | オディディ,イサ | オルガノゾル被膜を含む制御放出送達デバイス |
US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
CN101431992A (zh) | 2006-04-24 | 2009-05-13 | 万能药生物有限公司 | 包含尼美舒利的新型低剂量药物组合物及其制备和用途 |
US20070254027A1 (en) | 2006-04-28 | 2007-11-01 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
CA2651798C (en) | 2006-05-09 | 2015-07-21 | Mallinckrodt Inc. | Zero-order modified release solid dosage forms |
US7901885B2 (en) | 2006-05-09 | 2011-03-08 | Dsm Ip Assets B.V. | Genes and markers in type 2 diabetes and obesity |
US8377994B2 (en) | 2006-05-10 | 2013-02-19 | Evonik Degussa GmeH | Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
FR2901478B1 (fr) | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee |
US20070292508A1 (en) | 2006-06-05 | 2007-12-20 | Balchem Corporation | Orally disintegrating dosage forms |
US20070281016A1 (en) | 2006-06-06 | 2007-12-06 | Endo Pharmaceuticals Inc., A Delaware Corporation | Sustained release oxycodone composition with acrylic polymer and surfactant |
US20070281017A1 (en) | 2006-06-06 | 2007-12-06 | Endo Pharmaceuticals Inc., A Delaware Corporation | Sustained release oxycodone composition with acrylic polymer and metal hydroxide |
US20070286900A1 (en) | 2006-06-09 | 2007-12-13 | Catherine Herry | Low dose tablets of opioid analgesics and preparation process |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
PT2484346T (pt) | 2006-06-19 | 2017-04-26 | Alpharma Pharmaceuticals Llc | Composições farmacêuticas |
CA2654663A1 (en) | 2006-06-19 | 2007-12-27 | Mcneil-Ppc, Inc. | Enteric coated particles containing an active ingredient |
WO2008001341A1 (en) | 2006-06-27 | 2008-01-03 | Biovail Laboratories International Srl | Multiparticulate osmotic delivery system |
GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
EP2043613A1 (en) | 2006-07-14 | 2009-04-08 | Fmc Corporation | Solid form |
US20080014274A1 (en) | 2006-07-14 | 2008-01-17 | Wyeth | Enhanced stability phenylephrine liquid compositions |
US8765178B2 (en) | 2006-07-19 | 2014-07-01 | Watson Laboratories, Inc. | Controlled release formulations and associated methods |
CA2671200A1 (en) | 2006-07-21 | 2008-01-24 | Lab International Srl | Hydrophilic abuse deterrent delivery system |
US9005652B2 (en) | 2006-07-25 | 2015-04-14 | Wyeth | Chewable tablet containing phenylephrine |
KR20090027734A (ko) | 2006-07-27 | 2009-03-17 | (주)아모레퍼시픽 | 난용성 약물의 나노입자를 포함하는 분말의 제조방법 |
US20080026040A1 (en) | 2006-07-31 | 2008-01-31 | Isaac Farr | Active agent-releasing dosage forms |
US20080026062A1 (en) | 2006-07-31 | 2008-01-31 | Isaac Farr | Pharmaceutical compositions including nano-sized active agent |
US8603525B2 (en) | 2006-08-04 | 2013-12-10 | Ethypharm | Multilayer orally disintegrating tablet |
ES2667944T3 (es) | 2006-08-04 | 2018-05-16 | Ethypharm | Gránulos y comprimidos orodispersables que contienen oxicodona |
WO2008021394A2 (en) | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
WO2008027442A2 (en) | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
US20080057122A1 (en) | 2006-08-31 | 2008-03-06 | Aaipharma Inc. | Acetaminophen pharmaceutical compositions |
KR101468053B1 (ko) | 2006-08-31 | 2014-12-02 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템 |
WO2008033351A2 (en) | 2006-09-11 | 2008-03-20 | Theraquest Biosciences, Inc. | Multimodal abuse resistant and extended release formulations |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
KR20080026754A (ko) | 2006-09-21 | 2008-03-26 | 주식회사 삼양사 | 생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의제조방법 |
DE102006044694A1 (de) | 2006-09-22 | 2008-03-27 | Krewel Meuselbach Gmbh | Perorale feste Schmerzmittelzubereitung |
US20080081071A1 (en) | 2006-09-29 | 2008-04-03 | Pradeep Sanghvi | Film Embedded Packaging and Method of Making Same |
US20080085312A1 (en) | 2006-10-04 | 2008-04-10 | Auriga Laboratories, Inc. | Multi-Phase Release Potassium Guaiacolsulfonate Compositions |
PT2124556E (pt) | 2006-10-09 | 2014-12-03 | Charleston Lab Inc | Composições farmacêuticas |
US8653066B2 (en) | 2006-10-09 | 2014-02-18 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
US20080085304A1 (en) | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
JP5389656B2 (ja) | 2006-10-20 | 2014-01-15 | マクニール−ピーピーシー・インコーポレーテツド | アセトアミノフェン/イブプロフェンの組み合わせおよびこれらの使用方法 |
SI1940366T1 (sl) | 2006-10-24 | 2009-08-31 | Helsinn Healthcare Sa | Mehke kapsule, ki obsegajo palonosetron hidroklorid, z izboljšano stabilnostjo in biorazpoložljivostjo |
US20080102123A1 (en) | 2006-10-27 | 2008-05-01 | Schachter Deborah M | Self-gelling tunable drug delivery system |
MX2009004965A (es) | 2006-11-07 | 2009-06-05 | Nektar Therapeutics Al Corp | Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides. |
US7842662B2 (en) | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
WO2008057608A2 (en) | 2006-11-10 | 2008-05-15 | Cara Therapeutics, Inc. | Synthetic peptide amides |
US20080293695A1 (en) | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
WO2008063625A2 (en) | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
AU2007352557A1 (en) | 2006-11-22 | 2008-11-13 | Progenics Pharmaceuticals, Inc. | (S)-N-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs |
AU2007325315A1 (en) | 2006-11-28 | 2008-06-05 | Kalypsys Inc | Heterocyclic modulators of TGR5 |
US20080132751A1 (en) | 2006-11-30 | 2008-06-05 | Betazone Laboratories, Inc. | Compositions and methods for treatment of pain |
DK2101740T3 (da) | 2006-12-04 | 2013-11-18 | Orexo Ab | Nye ikke-misbrugs-farmaceutiske sammensætninger omfattende opioider |
EP2104493A2 (en) | 2007-01-16 | 2009-09-30 | Egalet A/S | Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse |
US20080221161A1 (en) | 2007-02-09 | 2008-09-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
WO2008100977A2 (en) | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
EP2129683A4 (en) | 2007-02-26 | 2011-01-05 | Ironwood Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS |
AR065494A1 (es) | 2007-03-02 | 2009-06-10 | Schering Corp | Derivados de piperidina y metodos de uso de los mismos |
US20100144591A1 (en) | 2007-03-02 | 2010-06-10 | Schering Corporation | Benzimidazole derivatives and methods of use thereof |
US20100166747A1 (en) | 2007-03-02 | 2010-07-01 | Beltran Pedro J | Methods and compositions for treating tumor diseases |
ATE440598T1 (de) | 2007-03-02 | 2009-09-15 | Flamek Corp Ou | Analgesische zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden arzneimitteln und opioiden |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
WO2008115811A2 (en) | 2007-03-16 | 2008-09-25 | Endo Pharmaceuticals, Inc. | Transdermal delivery form disposal systems and methods |
TWI417099B (zh) | 2007-03-23 | 2013-12-01 | Neuraxon Inc | 具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物 |
US20100080829A1 (en) | 2007-04-11 | 2010-04-01 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
EP1980245A1 (en) | 2007-04-11 | 2008-10-15 | Cephalon France | Bilayer lyophilized pharmaceutical compositions and methods of making and using same |
US20080260837A1 (en) | 2007-04-20 | 2008-10-23 | Qpharma, L.L.C. | Physically stable aqueous suspensions of active pharmaceuticals |
WO2008133928A2 (en) | 2007-04-27 | 2008-11-06 | The Gi Company, Inc. | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders |
NZ581362A (en) | 2007-04-27 | 2011-07-29 | Cydex Pharmaceuticals Inc | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
EP2073798A2 (en) | 2007-05-01 | 2009-07-01 | Sigmoid Pharma Limited | Pharmaceutical nimodipine compositions |
DE102007021549A1 (de) | 2007-05-08 | 2008-11-13 | Novosis Ag | Transdermales therapeutisches System enthaltend mindestens zwei Opioide |
WO2008141189A1 (en) | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
WO2008140459A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
WO2008140461A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
US20080286344A1 (en) | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
WO2008140460A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
US20080286343A1 (en) | 2007-05-16 | 2008-11-20 | Dzenana Cengic | Solid form |
US20080311162A1 (en) | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
US20080292683A1 (en) | 2007-05-24 | 2008-11-27 | Monosolrx, Llc. | Film shreds and delivery system incorporating same |
WO2008146178A2 (en) | 2007-05-30 | 2008-12-04 | Wockhardt Research Centre | A novel tablet dosage form |
US8202542B1 (en) | 2007-05-31 | 2012-06-19 | Tris Pharma | Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings |
WO2008148798A2 (en) | 2007-06-04 | 2008-12-11 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
US20100210604A1 (en) | 2007-06-13 | 2010-08-19 | Meythaler Jay M | Zwitterion solution for low-volume therapeutic delivery |
WO2008155620A1 (en) | 2007-06-20 | 2008-12-24 | Develco Pharma Schweiz Ag | Dosage form containing dispersible matrix of sustained release granules |
WO2009002299A1 (en) | 2007-06-22 | 2008-12-31 | Gluconova Llc | Method for treating warm-blooded vertebrates with halide-free glucosamine-acidic drug complexes |
US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
US20090004285A1 (en) | 2007-06-29 | 2009-01-01 | Liangping Yu | Stable non-disintegrating dosage forms and method of making same |
CA2690956C (en) | 2007-07-01 | 2017-01-03 | Joseph Peter Habboushe | Combination tablet with chewable outer layer |
EP2182928A1 (en) | 2007-07-20 | 2010-05-12 | Abbott GmbH & Co. KG | Formulations of nonopioid and confined opioid analgesics |
WO2009018169A1 (en) | 2007-07-27 | 2009-02-05 | Auspex Pharmaceuticals, Inc. | Substituted cyclohexanols |
JP2010535801A (ja) | 2007-08-06 | 2010-11-25 | シノシア・セラピューティクス・インコーポレイテッド | 依存症治療方法 |
WO2009023672A2 (en) | 2007-08-13 | 2009-02-19 | Abuse Deterrent Pharmaceutical Llc | Abuse resistant drugs, method of use and method of making |
US20090105124A1 (en) | 2007-08-23 | 2009-04-23 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
JP2010537989A (ja) | 2007-09-03 | 2010-12-09 | ナノセラピューティクス・インコーポレイテッド | 難溶性薬物の組成物及び送達方法 |
US20090068247A1 (en) | 2007-09-12 | 2009-03-12 | Mucosal Therapeutics | Biocompatible devices coated with a tribonectin and methods for their production |
CN101801354A (zh) | 2007-09-17 | 2010-08-11 | 麦克内尔-Ppc股份有限公司 | 含有由聚乙烯醇和聚乙二醇所成的共聚物和树胶的浸涂组合物 |
JP5204847B2 (ja) | 2007-09-21 | 2013-06-05 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | エタノールの影響に対して耐性を有するph依存性制御放出医薬オピオイド組成物 |
US20090087483A1 (en) | 2007-09-27 | 2009-04-02 | Sison Raymundo A | Oral dosage combination pharmaceutical packaging |
AU2008309681A1 (en) | 2007-10-01 | 2009-04-16 | Basf Se | Rodenticide mixture |
US20090110724A1 (en) | 2007-10-31 | 2009-04-30 | Everett Laboratories, Inc. | Compositions and methods for treatment of pain |
US20110020440A1 (en) | 2007-11-19 | 2011-01-27 | Cadila Pharmaceuticals Limited | Stable solutions of sparingly soluble actives |
WO2009073686A1 (en) | 2007-12-03 | 2009-06-11 | Trans Dermal Patents Company, Llc | Agent delivery system and uses of the same |
JP2011506318A (ja) | 2007-12-06 | 2011-03-03 | デュレクト コーポレーション | 経口医薬製剤 |
BRPI0820997A2 (pt) | 2007-12-10 | 2014-12-23 | Eurand Inc | Comprimidos de desintegração oral compreendendo difenidramina. |
RU2010129907A (ru) | 2007-12-17 | 2012-01-27 | Лабофарм Инк. (CA) | Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление |
CA2956278C (en) | 2008-01-04 | 2022-03-01 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine and applications thereof |
CA2749273C (en) | 2008-01-09 | 2018-09-04 | Charleston Laboratories, Inc. | Pharmaceutical oral dosage form comprising a triptan and an antiemetic |
US8497303B2 (en) | 2008-01-18 | 2013-07-30 | Dow Global Technologies Llc | Method to enhance aqueous solubility of poorly soluble actives |
JP5774853B2 (ja) | 2008-01-25 | 2015-09-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 医薬投薬形 |
EP2271330A1 (en) | 2008-02-01 | 2011-01-12 | Abbott Laboratories | Extended release hydrocodone acetaminophen and related methods and uses thereof |
US8088150B2 (en) | 2008-02-04 | 2012-01-03 | Aleeva Medical Inc. | Device for disc shunt implantation and peri-shunt injection |
JP2011511782A (ja) | 2008-02-12 | 2011-04-14 | アボット・ラボラトリーズ | 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途 |
KR101094231B1 (ko) | 2008-02-18 | 2011-12-14 | 하나제약 주식회사 | 서방성 고형 제제 및 그의 제조방법 |
RU2522493C2 (ru) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Способы лечения хронической боли |
JP5607550B2 (ja) | 2008-03-11 | 2014-10-15 | ディポメド,インコーポレイティド | 非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形 |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
CN102026627B (zh) | 2008-03-11 | 2016-10-26 | 武田药品工业株式会社 | 口腔崩解固体制剂 |
NZ588695A (en) | 2008-03-21 | 2012-11-30 | Mylan Pharmaceuticals Inc | Extended release forumulation containing a wax and ciprofloxacin |
EP2254561A2 (en) | 2008-03-26 | 2010-12-01 | AllTranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
US8623401B2 (en) | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
WO2009118764A1 (en) | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Pharmaceutical composition comprising diclofenac and paracetamol |
EP2106799A1 (en) | 2008-03-31 | 2009-10-07 | OWEN Holding LTD | Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor |
WO2009124755A1 (en) | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Compounds with novel medical uses and method of identifying such compounds |
JP5651291B2 (ja) | 2008-04-11 | 2015-01-07 | 株式会社センカファーマシー | ポリエチレングリコールの誘導体およびその中間体の製造方法 |
US8138169B2 (en) | 2008-04-11 | 2012-03-20 | Comgenrx, Inc. | Combination therapy for bipolar disorder |
US8420114B2 (en) | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
US8524267B2 (en) | 2008-04-18 | 2013-09-03 | Warsaw Orthopedic, Inc. | Dexamethasone formulations in a biodegradable material |
EP2273880B1 (en) | 2008-04-28 | 2014-12-31 | Zogenix, Inc. | Novel formulations for treatment of migraine |
AU2009245777B2 (en) | 2008-05-05 | 2013-06-06 | Euro-Celtique S.A. | Opioid composition for treating skin lesions |
CA2723685C (en) | 2008-05-07 | 2016-09-27 | Nektar Therapeutics | Oral administration of peripherally-acting opioid antagonists |
RU2010151952A (ru) | 2008-05-20 | 2012-06-27 | Ньюроджесэкс, Инк. (Us) | Водорастворимые аналоги ацетаминофена |
CA2724788C (en) | 2008-05-20 | 2016-12-06 | Neurogesx, Inc. | Hepatoprotectant acetaminophen mutual prodrugs |
EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
PT2299821E (pt) | 2008-06-10 | 2016-03-11 | Abbvie Inc | Compostos tricíclicos |
ZA200903858B (en) | 2008-06-19 | 2013-10-30 | Univ Of Witwatesrand Johannesburg | Pharmaceutical dosage form |
UA105182C2 (ru) | 2008-07-03 | 2014-04-25 | Ньюрексон, Інк. | Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность |
US20100003322A1 (en) | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
GB0813929D0 (en) | 2008-07-30 | 2008-09-03 | Glaxo Group Ltd | Novel method |
NZ592765A (en) | 2008-08-14 | 2013-06-28 | Bioneer As | Tablets with a coating which impedes the release of an active ingredient |
WO2010020856A2 (en) | 2008-08-19 | 2010-02-25 | Adcock Ingram Healthcare (Pty) Limited | Rate modulated delivery of drugs from a composite delivery system |
US20100076074A1 (en) | 2008-08-26 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Carbamate reducers of skeletal muscle tension |
JP5345813B2 (ja) | 2008-08-28 | 2013-11-20 | テイカ製薬株式会社 | オキシコドン経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤 |
US8067243B2 (en) | 2008-09-03 | 2011-11-29 | Oregon Medical Laboratories | Methods and systems for analyzing medication levels in a sample |
AU2009292631A1 (en) | 2008-09-16 | 2010-03-25 | Nektar Therapeutics | Pegylated opioids with low potential for abuse |
BRPI0913724B8 (pt) | 2008-09-18 | 2021-05-25 | Purdue Pharma Lp | formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo |
JP5453434B2 (ja) | 2008-09-24 | 2014-03-26 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | エタノールの影響に対する耐性を有するオピオイドではないpH依存の制御放出の医薬組成物 |
ES2592882T3 (es) | 2008-10-14 | 2016-12-02 | Mcneil Ab | Forma de dosificación intra-oral de múltiples porciones y uso de la misma |
WO2010044842A1 (en) | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
US20100098746A1 (en) | 2008-10-20 | 2010-04-22 | Warsaw Orthopedic, Inc. | Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone |
RU2673882C1 (ru) | 2008-10-30 | 2018-12-03 | Грюненталь Гмбх | Новые и эффективные лекарственные формы тапентадола |
US9072799B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US20100266682A1 (en) | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
US20100143486A1 (en) | 2008-12-10 | 2010-06-10 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
JP5667575B2 (ja) | 2008-12-16 | 2015-02-12 | パラディン ラブス インコーポレーテッド | 誤用を防止する放出制御製剤 |
US8362029B2 (en) | 2008-12-31 | 2013-01-29 | Upsher-Smith Laboratories, Inc. | Opioid-containing oral pharmaceutical compositions and methods |
US20100173013A1 (en) | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
NZ594071A (en) | 2009-01-26 | 2013-01-25 | Egalet Ltd | Controlled release formulations comprising morphine sulphate for continuous treatment of pain |
JP5408703B2 (ja) | 2009-01-30 | 2014-02-05 | 国立大学法人 千葉大学 | 薬剤及びその製造方法 |
DK2393487T3 (en) | 2009-02-06 | 2017-01-23 | Egalet Ltd | Pharmaceutical compositions resistant to abuse |
JP5878022B2 (ja) | 2009-02-23 | 2016-03-08 | アデア ファーマスーティカルズ,インコーポレイテッド | 抗コリン薬を具える放出制御組成物 |
NZ594513A (en) | 2009-03-04 | 2013-10-25 | Orexo Ab | Abuse resistant formulation |
WO2010103365A2 (en) | 2009-03-09 | 2010-09-16 | Council Of Scientific & Industrial Research | Sustained release composition of therapeutic agent |
US20110311628A1 (en) | 2009-03-09 | 2011-12-22 | Council Of Scientific And Industrial Research | Pulsatile release composition of therapeutic agent |
TR201900199T4 (tr) | 2009-03-10 | 2019-02-21 | Euro Celtique Sa | Oksikodon ve nalokson içeren çabuk salımlı farmasötik bileşimler. |
BRPI0924427A2 (pt) | 2009-03-18 | 2016-01-26 | Evonik Roehm Gmbh | composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma |
BRPI0924543B8 (pt) | 2009-03-18 | 2022-07-05 | Evonik Roehm Gmbh | composição farmacêutica de liberação controlada, e seu processo de preparação |
AU2010234339B2 (en) | 2009-04-09 | 2014-06-26 | Alkermes Pharma Ireland Limited | Drug delivery composition |
WO2010120389A2 (en) | 2009-04-17 | 2010-10-21 | Axxia Pharmaceuticals, Llc | Polymeric drug delivery systems and processes for producing such systems |
WO2010123999A2 (en) | 2009-04-21 | 2010-10-28 | Auspex Pharmaceuticals, Inc. | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor |
WO2010124089A2 (en) | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
RU2567032C2 (ru) | 2009-05-01 | 2015-10-27 | Апталис Фарматек, Инк. | Перорально распадающиеся таблеточные композиции, содержащие комбинации неопиоидных и опиоидных анальгетиков |
US11135188B2 (en) | 2009-05-11 | 2021-10-05 | Bayer Healthcare Llc | Method and composition to improve absorption of therapeutic agents |
WO2013170052A1 (en) | 2012-05-09 | 2013-11-14 | Sio2 Medical Products, Inc. | Saccharide protective coating for pharmaceutical package |
US20100291201A1 (en) | 2009-05-14 | 2010-11-18 | Cerovene, Inc. | Coated pharmaceutical capsule dosage form |
CA2762216C (en) | 2009-05-18 | 2017-07-11 | 3M Innovative Properties Company | Dry powder inhalers |
US20120064159A1 (en) | 2009-05-28 | 2012-03-15 | Aptapharma, Inc. | Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen |
WO2010141505A1 (en) | 2009-06-01 | 2010-12-09 | Protect Pharmaceutical Corporation | Abuse-resistant delivery systems |
US20100304998A1 (en) | 2009-06-02 | 2010-12-02 | Marquette University | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins |
GB0909680D0 (en) | 2009-06-05 | 2009-07-22 | Euro Celtique Sa | Dosage form |
FR2946533A1 (fr) | 2009-06-12 | 2010-12-17 | Ethypharm Sa | Reduction des fluctuations plasmatiques d'opioides. |
AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
KR101074271B1 (ko) | 2009-06-25 | 2011-10-17 | (주)차바이오앤디오스텍 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
US20110020776A1 (en) | 2009-06-25 | 2011-01-27 | Certusview Technologies, Llc | Locating equipment for and methods of simulating locate operations for training and/or skills evaluation |
WO2010150930A1 (ko) | 2009-06-25 | 2010-12-29 | (주)벡스코아 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
RU2535038C2 (ru) | 2009-06-25 | 2014-12-10 | Криэлта Фармасьютикалз ЭлЭлСи | Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови |
US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
EP3311667A1 (en) | 2009-07-08 | 2018-04-25 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
WO2011008298A2 (en) | 2009-07-16 | 2011-01-20 | Nectid, Inc. | Novel axomadol dosage forms |
JP5837491B2 (ja) | 2009-07-21 | 2015-12-24 | ウェルズ ファーゴ バンク ナショナル アソシエイション | オリゴマー−オピオイドアゴニスト抱合体 |
CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
JP2012533586A (ja) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 酸化安定化された不正使用防止剤形 |
EP3646870A1 (en) | 2009-07-22 | 2020-05-06 | Puretech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
ES2833035T3 (es) | 2009-07-31 | 2021-06-14 | Ascendis Pharma As | Hidrogeles biodegradables insolubles en agua a base de polietilenglicol |
AU2010286354A1 (en) | 2009-08-31 | 2012-04-19 | Depomed, Inc. | Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen |
WO2011039768A2 (en) | 2009-09-17 | 2011-04-07 | Cadila Healthcare Limited | Pharmaceutical compositions for reducing alcohol-induced dose dumping |
US8901113B2 (en) | 2009-09-30 | 2014-12-02 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
FR2951378B1 (fr) | 2009-10-16 | 2012-06-01 | Flamel Tech Sa | Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee |
US20110104272A1 (en) | 2009-11-05 | 2011-05-05 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine |
WO2011057199A1 (en) | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
SG10201407947WA (en) | 2009-11-30 | 2015-01-29 | Aptalis Pharmatech Inc | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture |
AR079234A1 (es) | 2009-12-01 | 2012-01-04 | Abbott Lab | Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar afecciones oncologicas, del sistema nervioso y/o del sistema inmune. |
WO2011066980A2 (en) | 2009-12-04 | 2011-06-09 | Lars Holger Hermann | Oral dosage forms with reduced potential for drug abuse |
JP5894717B2 (ja) | 2009-12-17 | 2016-03-30 | シマ ラブス インク. | 乱用抑止性製剤 |
US8597681B2 (en) | 2009-12-22 | 2013-12-03 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US20110150989A1 (en) | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
WO2011087755A2 (en) | 2009-12-22 | 2011-07-21 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
WO2011079074A1 (en) | 2009-12-24 | 2011-06-30 | Acura Phamaceuticals, Inc. | Pharmaceutical compositions for deterring misuse, abuse, and diversion |
WO2011088140A1 (en) | 2010-01-12 | 2011-07-21 | Nektar Therapeutics | Pegylated opioids with low potential for abuse and side effects |
EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
US20120321674A1 (en) | 2011-02-17 | 2012-12-20 | Michael Vachon | Technology for Preventing Abuse of Solid Dosage Forms |
US20110195989A1 (en) | 2010-02-09 | 2011-08-11 | Rudnic Edward M | Controlled Release Formulations of Opioids |
US20130022646A1 (en) | 2010-02-09 | 2013-01-24 | Rudnic Edward M | Controlled Release Formulations of Opioids |
US20110195398A1 (en) | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Systems and methods for detecting insulin resistance biomarkers |
US20110195520A1 (en) | 2010-02-11 | 2011-08-11 | Ameritox, Ltd. | Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen |
US9125867B2 (en) | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
WO2011107855A2 (en) | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
GB201003731D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
US20110218209A1 (en) | 2010-03-06 | 2011-09-08 | Paul Daniel Yered | Nutrient delievry drug composition |
US20110230816A1 (en) | 2010-03-18 | 2011-09-22 | Tyco Healthcare Group Lp | Gels for Transdermal Delivery |
IT1398930B1 (it) | 2010-03-24 | 2013-03-28 | Molteni & C | Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi. |
ES2829386T3 (es) | 2010-03-30 | 2021-05-31 | Phosphagenics Ltd | Parche de administración transdérmica |
JP2013523764A (ja) | 2010-03-30 | 2013-06-17 | アルジーノミクス インコーポレイテッド | 体性感覚障害治療用の組成物と方法 |
US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
US20110239745A1 (en) | 2010-04-01 | 2011-10-06 | Lawrence Livermore National Security, Llc | Rapid Identification of Explosives Using Thin-Layer Chromatography and Colorimetric Techniques |
WO2011123866A1 (en) | 2010-04-02 | 2011-10-06 | Alltranz Inc. | Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists |
WO2011127467A1 (en) | 2010-04-09 | 2011-10-13 | Companion Diagnostics, Inc. | Devices, systems, and methods for biomarker stabilization |
WO2011139595A2 (en) | 2010-04-27 | 2011-11-10 | Medtronic, Inc. | Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain |
WO2011141490A1 (en) | 2010-05-10 | 2011-11-17 | Euro-Celtique S.A. | Combination of active loaded granules with additional actives |
MX340188B (es) | 2010-05-10 | 2016-06-30 | Euro-Celtique S A * | Elaboracion de granulos sin activos y tabletas que comprenden los mismos. |
US20130059010A1 (en) | 2010-05-14 | 2013-03-07 | Ethypharm | Alcohol-resistant oral pharmaceutical form |
CN101824144A (zh) | 2010-05-15 | 2010-09-08 | 西北师范大学 | 聚乙二醇芳氧乙酸酯及其制备和作为植物生长调节剂的应用 |
CA3065589C (en) | 2010-06-03 | 2022-04-26 | Catalent Ontario Limited | Multi phase soft gel capsules, apparatus and method thereof |
JP2011256115A (ja) | 2010-06-04 | 2011-12-22 | Michishi Tani | 自閉症の治療薬 |
FR2960775A1 (fr) | 2010-06-07 | 2011-12-09 | Ethypharm Sa | Microgranules resistants au detournement |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
AU2011271429B2 (en) | 2010-06-30 | 2016-04-21 | Upsher-Smith Laboratories, Llc | Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid |
US20120141554A1 (en) | 2010-07-08 | 2012-06-07 | Wellesley Pharmaceuticals, Llc | Delayed release formulation for reducing the frequency of urination and method of use thereof |
AR082167A1 (es) | 2010-07-14 | 2012-11-14 | Gruenenthal Gmbh | Formas de dosificacion gastrorretentivas |
CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
US9526600B2 (en) | 2010-07-20 | 2016-12-27 | Warsaw Orthopedic, Inc. | Biodegradable stents and methods for treating periodontal disease |
US20120022009A1 (en) | 2010-07-21 | 2012-01-26 | Acella Pharmaceuticals, Llc | Tannate dry powder formulations |
WO2012011917A1 (en) | 2010-07-23 | 2012-01-26 | Activbiotics Pharma, Llc | Administration of rifalazil to immunocompromised patients |
MX2013001234A (es) | 2010-08-05 | 2013-04-24 | Conrig Pharma Aps | Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a. |
EP2603205B1 (en) | 2010-08-13 | 2018-10-03 | Euro-Celtique S.A. | Use of binders for manufacturing storage stable formulations |
WO2012021819A1 (en) | 2010-08-13 | 2012-02-16 | Acura Pharmaceuticals, Inc. | Optimized niacin compositions in pharmaceutical products |
FR2963889B1 (fr) | 2010-08-20 | 2013-04-12 | Debregeas Et Associes Pharma | Formulations a base de nalbuphine et leurs utilisations |
US8507844B2 (en) | 2010-08-31 | 2013-08-13 | Waters Technologies Corporation | Techniques for sample analysis |
CN101926757B (zh) | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
NZ608865A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising an anionic polymer |
PE20131125A1 (es) | 2010-09-02 | 2013-10-21 | Gruenenthal Chemie | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
AU2011297901B2 (en) | 2010-09-02 | 2014-07-31 | Grunenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
WO2012037457A1 (en) | 2010-09-16 | 2012-03-22 | Cornell University | Use of adenosine receptor signaling to modulate permeability of blood-brain barrier |
ES2753981T3 (es) | 2010-10-21 | 2020-04-15 | Rtu Pharmaceuticals Llc | Formulaciones de ketorolaco listas para uso |
EP2444064A1 (en) | 2010-10-22 | 2012-04-25 | Meliatys | Process for making multiparticulate gastroretentive dosage forms |
US8685381B2 (en) | 2010-10-23 | 2014-04-01 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
US20120100183A1 (en) | 2010-10-23 | 2012-04-26 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
EP2635258A1 (en) | 2010-11-04 | 2013-09-11 | AbbVie Inc. | Drug formulations |
US20130230587A1 (en) | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
KR101965002B1 (ko) | 2010-12-02 | 2019-08-13 | 아데어 파마슈티컬스 인코포레이티드 | 급속 분산성 과립, 구강 붕해성 정제 및 방법 |
EP2649443A2 (en) | 2010-12-06 | 2013-10-16 | Ramot at Tel-Aviv University Ltd | Methods and kits for detection of drugs |
GB201020895D0 (en) | 2010-12-09 | 2011-01-26 | Euro Celtique Sa | Dosage form |
WO2012080833A2 (en) | 2010-12-13 | 2012-06-21 | Purdue Pharma L.P. | Controlled release dosage forms |
SG10201510564PA (en) | 2010-12-22 | 2016-01-28 | Purdue Pharma Lp | Encased tamper resistant controlled release dosage forms |
WO2012085236A1 (en) | 2010-12-23 | 2012-06-28 | Abbott Gmbh & Co. Kg | Solid retard formulations based on solid dispersions |
KR20140075807A (ko) | 2010-12-23 | 2014-06-19 | 퍼듀 퍼머 엘피 | 탬퍼 저항성 고체 경구 투여 형태 |
US8518438B2 (en) | 2011-01-14 | 2013-08-27 | Enspire Group, Llc | Highly concentrated liquid acetaminophen solutions |
WO2012098281A2 (es) | 2011-01-19 | 2012-07-26 | Universidad Miguel Hernández De Elche | Péptidos moduladores de receptores trp y sus usos |
USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
CA2827273A1 (en) | 2011-02-17 | 2012-08-23 | QRxPharma Ltd. | Technology for preventing abuse of solid dosage forms |
EP2675893B1 (en) | 2011-02-18 | 2019-01-09 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
CN102648985B (zh) | 2011-02-24 | 2014-03-26 | 温州中科应急急救包有限公司 | 壳聚糖急救止血材料 |
JP6043733B2 (ja) | 2011-02-25 | 2016-12-14 | アリーナ ファーマシューティカルズ, インコーポレイテッド | カンナビノイド受容体モジュレーター |
WO2012116278A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
KR101077468B1 (ko) | 2011-03-04 | 2011-11-07 | (주)차바이오앤디오스텍 | 안정한 경구용 속용 필름 제제 |
JP6277121B2 (ja) | 2011-03-22 | 2018-02-07 | アドヴィナス・セラピューティックス・リミテッド | 置換された縮合三環式化合物、その組成物および医学的応用 |
US20140056979A1 (en) | 2011-03-25 | 2014-02-27 | Purdue Pharma L.P. | Controlled Release Pharmaceutical Dosage Forms |
BRPI1106121A2 (pt) | 2011-11-25 | 2015-12-08 | Univ Minas Gerais | composições farmacêuticas contendo 11, 12-pirazolminociclina e uso para alívio de dor de origem neuropática |
US20120289534A1 (en) | 2011-05-11 | 2012-11-15 | Kirax Corporation | Package for improved treatment of conditions |
US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
CA2840215A1 (en) | 2011-06-22 | 2012-12-27 | Abhijit S. BAPAT | Conjugate-based antifungal and antibacterial prodrugs |
US8623377B2 (en) | 2011-06-29 | 2014-01-07 | University Of Maryland, Baltimore | Joint-homing peptides and uses thereof |
WO2013003845A1 (en) | 2011-06-30 | 2013-01-03 | Neos Therapeutics, Lp | Abuse resistant drug forms |
PL2726064T3 (pl) | 2011-06-30 | 2017-06-30 | Develco Pharma Schweiz Ag | Doustna postać użytkowa o kontrolowanym uwalnianiu zawierająca oksykodon |
CN102344534A (zh) | 2011-07-12 | 2012-02-08 | 天津工业大学 | 含扑热息痛结构的聚甲基聚乙二醇丙烯酸酯及其制备方法和使用方法 |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
US20130028955A1 (en) | 2011-07-25 | 2013-01-31 | Gaurav Thakersi Tolia | Sustained release oral matrix and methods of making thereof |
US8579924B2 (en) | 2011-07-26 | 2013-11-12 | Covidien Lp | Implantable devices including a mesh and a pivotable film |
KR101303479B1 (ko) | 2011-07-28 | 2013-09-06 | (주)씨엘팜 | 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제 |
CN103841964A (zh) | 2011-07-29 | 2014-06-04 | 格吕伦塔尔有限公司 | 提供药物立即释放的抗破碎片剂 |
PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
CN102389423A (zh) | 2011-09-09 | 2012-03-28 | 北京阜康仁生物制药科技有限公司 | 一种含有布洛芬钠盐的药用组合物 |
AU2012310250B2 (en) | 2011-09-16 | 2016-03-03 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
MX347961B (es) | 2011-09-16 | 2017-05-19 | Purdue Pharma Lp | Formulaciones de liberación inmediata resistentes a alteración. |
CA2847613A1 (en) | 2011-09-16 | 2013-03-21 | Purdue Pharma L.P. | Tamper resistant immediate release formulations |
AU2012320496C1 (en) | 2011-10-06 | 2017-09-28 | Grünenthal GmbH | Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist |
US20140323512A1 (en) | 2011-10-18 | 2014-10-30 | Purdue Pharma L.P. | Acrylic Polymer Formulations |
JP2014531031A (ja) | 2011-10-21 | 2014-11-20 | デシマドックス, エルエルシー | 小分析物の定量的検出のためのポイントオブケア免疫アッセイ |
MX347135B (es) | 2011-10-21 | 2017-04-12 | Dae Woong Pharma | Composición farmacéutica de sabor enmascarado para administración oral, y proceso para la preparación de la misma. |
KR101203186B1 (ko) | 2011-10-21 | 2012-11-23 | 주식회사 대웅제약 | 약물의 맛이 차폐된 경구용 약학 조성물 및 그 제조 방법 |
US9005308B2 (en) | 2011-10-25 | 2015-04-14 | Covidien Lp | Implantable film/mesh composite for passage of tissue therebetween |
US8932621B2 (en) | 2011-10-25 | 2015-01-13 | Covidien Lp | Implantable film/mesh composite |
WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
CN103906522B (zh) | 2011-11-07 | 2017-04-12 | 尼克塔治疗公司 | 阿片激动剂化合物和止痛化合物的组合物、剂型以及共给药 |
US20130122098A1 (en) | 2011-11-14 | 2013-05-16 | Bayer Healthcare Llc | Method and composition to improve absorption of therapeutic agents |
WO2013072395A1 (en) | 2011-11-17 | 2013-05-23 | Grünenthal GmbH | Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
CA2853764C (en) | 2011-11-22 | 2017-05-16 | Watson Pharmaceuticals, Inc. | Immediate release abuse deterrent tablet |
WO2013082308A1 (en) | 2011-11-30 | 2013-06-06 | Children's Hospital Medical Center | Personalized pain management and anesthesia: preemptive risk identification and therapeutic decision support |
FR2983409B1 (fr) | 2011-12-06 | 2013-12-27 | Ethypharm Sa | Comprime susceptible de lutter contre le detournement par voie injectable |
EP2787978B1 (en) | 2011-12-09 | 2016-09-21 | Purdue Pharma LP | Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide |
WO2013093877A2 (en) | 2011-12-23 | 2013-06-27 | Koninklijke Philips Electronics N.V. | Encapsulation system for controlled release of a bleaching agent |
US9095840B2 (en) | 2012-01-03 | 2015-08-04 | The Penn State Research Foundation | Nitrogen-containing activated carbon material |
US9399123B2 (en) | 2012-01-04 | 2016-07-26 | Momentive Performance Materials Inc. | Silicone adhesive compositions |
WO2013119231A1 (en) | 2012-02-09 | 2013-08-15 | Tris Pharma, Inc. | Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings |
GB201202223D0 (en) | 2012-02-09 | 2012-03-28 | Randox Lab Ltd | Immunoassay for pyrrolidinophenones |
CN103040829B (zh) | 2012-02-17 | 2015-02-11 | 北京人福军威医药技术开发有限公司 | 含有高乌甲素和羟考酮的药物组合物 |
US10549052B2 (en) | 2012-02-28 | 2020-02-04 | Sipnose Ltd. | Nasal delivery device |
US20130225412A1 (en) | 2012-02-28 | 2013-08-29 | Soroush Sardari Lodriche | Silicon nanocarrier for delivery of drug, pesticides and herbicides , and for waste water treatment |
JP6117249B2 (ja) | 2012-02-28 | 2017-04-19 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形 |
US20130225625A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant |
NZ629468A (en) | 2012-03-02 | 2017-08-25 | Rhodes Pharmaceuticals Lp | Tamper resistant immediate release formulations |
WO2013138118A1 (en) | 2012-03-14 | 2013-09-19 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
PL2825208T3 (pl) | 2012-03-14 | 2017-10-31 | Levicept Ltd | Białko wiążące neurotrofinę P75NTR do zastosowania terapeutycznego |
WO2013151638A1 (en) | 2012-04-06 | 2013-10-10 | Indus Pharmaceuticals, Inc. | Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment |
US9687445B2 (en) | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
WO2013155430A1 (en) | 2012-04-13 | 2013-10-17 | Banner Pharmacaps, Inc. | Soft elastic capsules containing tablets and liquid or semisolid fills and methods for their manufacture |
ES2644935T3 (es) | 2012-04-18 | 2017-12-01 | Mallinckrodt Llc | Composiciones farmacéuticas de liberación inmediata con propiedades disuasorias del abuso |
WO2013156453A1 (en) | 2012-04-18 | 2013-10-24 | Grünenthal GmbH | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
ES2699806T3 (es) | 2012-04-18 | 2019-02-12 | SpecGx LLC | Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
WO2013171146A1 (en) | 2012-05-15 | 2013-11-21 | Lts Lohmann Therapie-Systeme Ag | Oral film containing enteric release opiate resinate |
WO2013175511A1 (en) | 2012-05-24 | 2013-11-28 | V.B. Medicare Pvt. Ltd. | Taste masked pharmaceutical compositions |
JP2013249458A (ja) | 2012-06-04 | 2013-12-12 | Hitachi Chemical Co Ltd | 封止用エポキシ樹脂成形材料及び電子部品装置 |
DE102012105512A1 (de) | 2012-06-25 | 2014-04-24 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur verlängerten Freisetzung von Wirkstoffen |
WO2014004126A1 (en) | 2012-06-26 | 2014-01-03 | Fleming C Andrew | Treating postoperative nausea and vomiting |
CN104582733B (zh) | 2012-06-27 | 2017-07-04 | 美蒂森 | 用于疏水性组合物的可生物降解的药物释放*** |
MX362838B (es) | 2012-07-12 | 2019-02-19 | SpecGx LLC | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. |
US20140045801A1 (en) | 2012-08-09 | 2014-02-13 | Mylan Inc. | Pramipexole transdermal delivery for severe headaches |
US9593115B2 (en) | 2012-09-21 | 2017-03-14 | Advinus Therapeutics Ltd. | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof |
CA2791206A1 (en) | 2012-09-28 | 2014-03-28 | Pharmascience Inc. | Abuse deterrent pharmaceutical formulation |
US10987365B2 (en) | 2012-10-01 | 2021-04-27 | Gm Pharmaceuticals, Inc. | Compositions and methods for the treatment of pain |
WO2014059512A1 (en) | 2012-10-15 | 2014-04-24 | Isa Odidi | Oral drug delivery formulations |
CN103070840A (zh) | 2012-10-31 | 2013-05-01 | 北京正大绿洲医药科技有限公司 | 盐酸羟考酮缓释滴丸及其制备方法 |
CN113712911A (zh) * | 2013-03-15 | 2021-11-30 | 维普詹尼克斯公司 | 新型镇痛组合物 |
WO2015023704A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
CN103637987B (zh) | 2013-12-09 | 2015-12-02 | 韩彬 | 羟考酮的液体药物组合物 |
CN103637998B (zh) | 2013-12-09 | 2016-04-06 | 韩彬 | 包含羟考酮和罗通定的缓释片剂 |
WO2015157150A1 (en) | 2014-04-07 | 2015-10-15 | Banner Life Sciences Llc | Opioid abuse-deterrent controlled release formulations |
-
2015
- 2015-07-07 US US14/792,699 patent/US9707184B2/en active Active
- 2015-07-07 CA CA2955229A patent/CA2955229C/en not_active Expired - Fee Related
- 2015-07-07 DK DK15821947.7T patent/DK3169315T3/da active
- 2015-07-07 AU AU2015290098A patent/AU2015290098B2/en not_active Ceased
- 2015-07-07 ES ES15821947T patent/ES2809458T3/es active Active
- 2015-07-07 WO PCT/US2015/039336 patent/WO2016010771A1/en active Application Filing
- 2015-07-07 EP EP15821947.7A patent/EP3169315B1/en active Active
- 2015-07-07 JP JP2017502652A patent/JP6371463B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-13 US US15/621,285 patent/US20170340574A1/en not_active Abandoned
-
2018
- 2018-07-12 JP JP2018131927A patent/JP2018197241A/ja active Pending
-
2019
- 2019-01-03 AU AU2019200026A patent/AU2019200026A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009523833A (ja) * | 2006-01-21 | 2009-06-25 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 乱用薬剤送達のための製剤および方法 |
US20100204259A1 (en) * | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
JP2013537915A (ja) * | 2010-09-24 | 2013-10-07 | キューアールエックスファーマ リミテッド | オピオイドの制御放出製剤 |
US20140010873A1 (en) * | 2012-07-06 | 2014-01-09 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
Also Published As
Publication number | Publication date |
---|---|
EP3169315B1 (en) | 2020-06-24 |
EP3169315A4 (en) | 2018-03-21 |
DK3169315T3 (da) | 2020-08-10 |
US20170340574A1 (en) | 2017-11-30 |
AU2015290098B2 (en) | 2018-11-01 |
WO2016010771A1 (en) | 2016-01-21 |
JP2018197241A (ja) | 2018-12-13 |
US20160015650A1 (en) | 2016-01-21 |
EP3169315A1 (en) | 2017-05-24 |
ES2809458T3 (es) | 2021-03-04 |
CA2955229C (en) | 2020-03-10 |
JP6371463B2 (ja) | 2018-08-08 |
AU2019200026A1 (en) | 2019-01-24 |
AU2015290098A1 (en) | 2017-01-19 |
CA2955229A1 (en) | 2016-01-21 |
US9707184B2 (en) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2913368C (en) | Abuse deterrent immediate release formulation | |
JP6539274B2 (ja) | 押出成形された即放性乱用抑止性丸剤 | |
TWI463983B (zh) | 抗干預之劑型 | |
CA2869450C (en) | Oral film containing opiate enteric-release beads | |
US20190117781A1 (en) | Immediate release abuse deterrent formulations | |
JP6371463B2 (ja) | 即時放出性乱用抑止性液体充填剤形 | |
US10959958B2 (en) | Extended release abuse deterrent liquid fill dosage form | |
KR20190028656A (ko) | 내마모성 오피오이드 제형 | |
JP6678212B2 (ja) | 押出成形された持続放出性乱用抑止性丸剤 | |
CA3002181C (en) | Food independent immediate release drug formulation with abuse deterrence and overdose protection | |
CA3071261A1 (en) | Oral tablet formulations | |
BR112018014839B1 (pt) | Forma de dosagem sólida contendo glucomanano com liberação prolongada e propriedades para evitar o uso abusivo e seu processo de preparação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170306 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171031 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180427 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180612 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180712 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6371463 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |